Sacituzumab govitecan, sold under the brand name Trodelvy by Gilead Sciences, is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate...
30 KB (2,407 words) - 19:47, 1 July 2024
inhibitor mTNBC -PD-L1: 1st line: single-agent chemo; 3rd line: sacituzumab govitecan mTNBC +BRCA: patients previously treated with chemotherapy in the...
28 KB (3,411 words) - 03:40, 14 June 2024
Washkowitz S, Sharkey RM, Wegener WA, Kalinsky K (February 2019). "Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer". N...
40 KB (4,269 words) - 10:29, 26 June 2024
survival. In April 2021, the FDA granted accelerated approval to sacituzumab govitecan for people with locally advanced or metastatic urothelial cancer...
19 KB (1,988 words) - 16:26, 11 March 2024
neuroendocrine prostate cancers. This antigen is the target of sacituzumab govitecan and datopotamab deruxtecan (Dato-DXd), both antibody-drug conjugates...
10 KB (1,213 words) - 14:21, 28 May 2024
June 2023. Retrieved 28 June 2023 – via PR Newswire. "Trodelvy- sacituzumab govitecan powder, for solution". DailyMed. Archived from the original on 20...
135 KB (4,054 words) - 22:35, 2 July 2024
"IrinotecanPathway_WP229". NK012, a nanodevice formulation of SN-38 Sacituzumab govitecan, an antibody-drug conjugate that uses SN-38 as the cytotoxic drug...
3 KB (225 words) - 16:48, 11 January 2024
Review. [1] "Immunomedics Awarded Fast Track Designation by FDA for Sacituzumab Govitecan (IMMU-132) for Triple-Negative Breast Cancer Therapy". GlobeNewswire...
7 KB (808 words) - 17:52, 28 February 2024
($88 per share), gaining control of the cancer treatment Trodelvy (Sacituzumab govitecan-hziy) – a first-in-class Trop-2 antibody-drug conjugate. In December...
78 KB (7,557 words) - 02:24, 25 June 2024
coronavirus SARS-CoV-2 Pegvaliese (Palynziq) for phenylketonuria Sacituzumab govitecan (Trodelvy) for urinary tract cancers The graduate program at Scripps...
24 KB (2,404 words) - 04:25, 1 June 2024
antibody in phase III trials for pediatric leukemia.[citation needed] Sacituzumab govitecan (IMMU-132 / Trodelvy) is an anti-Trop-2-SN-38 antibody-drug conjugate...
5 KB (401 words) - 18:44, 18 June 2024
Polatuzumab vedotin Prolgolimab Ramucirumab Retifanlimab Sabatolimab Sacituzumab govitecan Serplulimab Sugemalimab Tafasitamab Talquetamab Tarlatamab Teclistamab...
12 KB (760 words) - 05:52, 10 June 2024
Pemigatinib Incyte Corp metastatic cholangiocarcinoma with FGFR2 fusion Sacituzumab govitecan-hziy Immunomedics metastatic triple-negative breast cancer Capmatinib...
34 KB (180 words) - 22:09, 8 April 2024
conjugates: trastuzumab emtansine (2013), trastuzumab deruxtecan (2019), sacituzumab govitecan (2020). Medical imaging is frequently used in breast cancer management...
53 KB (6,748 words) - 01:23, 10 February 2024
L01FX15 Belantamab mafodotin L01FX16 Oportuzumab monatox L01FX17 Sacituzumab govitecan L01FX18 Amivantamab L01FX19 Sabatolimab L01FX20 Tremelimumab L01FX21...
12 KB (877 words) - 15:36, 25 January 2024
Polatuzumab vedotin Prolgolimab Ramucirumab Retifanlimab Sabatolimab Sacituzumab govitecan Serplulimab Sugemalimab Tafasitamab Talquetamab Tarlatamab Teclistamab...
12 KB (758 words) - 23:46, 14 March 2024
vedotin§ Polatuzumab vedotin Rosmantuzumab Rovalpituzumab tesirine† Sacituzumab govitecan Sibrotuzumab§ Simtuzumab§ Sofituzumab vedotin§ Tacatuzumab tetraxetan§...
5 KB (368 words) - 22:00, 19 October 2020
vedotin§ Polatuzumab vedotin Rosmantuzumab Rovalpituzumab tesirine† Sacituzumab govitecan Sibrotuzumab§ Simtuzumab§ Sofituzumab vedotin§ Tacatuzumab tetraxetan§...
4 KB (241 words) - 11:41, 22 April 2022
vedotin§ Polatuzumab vedotin Rosmantuzumab Rovalpituzumab tesirine† Sacituzumab govitecan Sibrotuzumab§ Simtuzumab§ Sofituzumab vedotin§ Tacatuzumab tetraxetan§...
3 KB (129 words) - 01:04, 19 July 2023